Drug Profile
Research programme: antibody-based therapeutics - BioAtla
Alternative Names: CAB-ADCLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator BioAtla
- Class Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Colorectal cancer; Crohn's disease; Haematological malignancies; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Ulcerative colitis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Crohn's-disease in USA (Parenteral)